Innovative drugs that address antibiotic resistance

Destiny Pharma’s focus is on the clinical development and commercial exploitation of the highly innovative antibacterial, 1st in class pharmaceutical platform – the XF Drug Series. The Company’s science and products are underpinned by an established international collaborative network within industry and governments.

Our innovative drug development process has already produced the revolutionary XF drug series, with a lead drug, XF-73, (exeporfinium chloride), already in clinical development in the EU & US. This drug has been awarded Qualifying Infectious Disease Product status by the FDA for a new US indication of The Prevention of Post-Surgical Staphylococcal Infections.

Evidence shows that the likelihood of bacterial resistance developing to these drugs is remote – offering a totally new means to prevent and treat bacterial infections.